AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11474662 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept 0.150 mg/kg
Number of subjects: 229
Study 11474662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 11474662 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept
Number of subjects: 229
Study 9727378 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide stimulation for 20 hours
Number of subjects: 0
Study 9727378 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 0
Study 9727378 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis patients
Number of subjects: 0
Study 7508536 — intervention group
Group type: EXPERIMENTAL
Intervention: FK‐506 plus prednisone
Number of subjects: 37
Study 7508536 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A (CSA) plus prednisone and azathioprine
Number of subjects: 37
Study 2837830 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant CAP chemotherapy
Number of subjects: 0
Study 2837830 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone or in combination with radiation therapy
Number of subjects: 0
Study 2837830 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative therapy (chemotherapy alone or combination with radiation) followed by adjuvant chemotherapy
Number of subjects: 0
Study 2837830 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy directed at CNS disease
Number of subjects: 0
Study 29608807 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS) + Peripheral Nerve Field Stimulation (PNFS)
Number of subjects: 50
Study 29608807 — intervention group
Group type: COMPARATOR
Intervention: Spinal Cord Stimulation (SCS) alone
Number of subjects: 50
Study 28372326 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (CR) intervention group (IG) performing twelve sessions of CR over three months.
Number of subjects: 16
Study 28372326 — intervention group
Group type: COMPARATOR
Intervention: Standardized cognitive training in the active control group (CG).
Number of subjects: 16
Study 28372326 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IG and CG).
Number of subjects: 16
Study 26215778 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative Atrial Fibrillation (POAF)
Number of subjects: 398
Study 23622913 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent percutaneous transvenous mitral annuloplasty (PTMA) device
Number of subjects: 43
Study 21707327 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Number of subjects: 100
Study 21707327 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 100
Study 21707327 — intervention group
Group type: COMPARATOR
Intervention: Testosterone gel vs Placebo gel
Number of subjects: 100
Study 18622011 — intervention group
Group type: EXPERIMENTAL
Intervention: Theater-based after-school program 'Ready. Set. ACTION!'
Number of subjects: 96
Study 18622011 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 96
Study 16443774 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose insulin (0.3 mU . kg(‐1) . min(‐1)) in HNF-1beta mutation carriers
Number of subjects: 18
Study 16443774 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose insulin (0.3 mU . kg(‐1) . min(‐1)) in HNF-1alpha mutation carriers
Number of subjects: 18
Study 16443774 — intervention group
Group type: COMPARATOR
Intervention: Low-dose insulin (0.3 mU . kg(‐1) . min(‐1)) in control subjects
Number of subjects: 18
Study 16443774 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose insulin (1.5 mU . kg(‐1) . min(‐1)) in all groups
Number of subjects: 18
Study 14693773 — intervention group
Group type: EXPERIMENTAL
Intervention: Flicker light (12.5 Hz, 530‐600 nm, duration 20 seconds)
Number of subjects: 5
Study 11467238 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (250 mg)
Number of subjects: 24
Study 11467238 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg)
Number of subjects: 24
Study 11467238 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined regimen of acetazolamide and dexamethasone (twice daily for 5 days)
Number of subjects: 24
Study 11467238 — intervention group
Group type: COMPARATOR
Intervention: Placebo (multivitamin)
Number of subjects: 24
Study 9479673 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye movement desensitization and reprocessing (EMDR) (n = 10)
Number of subjects: 35
Study 9479673 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback‐assisted relaxation (n = 13)
Number of subjects: 35
Study 9479673 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical care (control) (n = 12)
Number of subjects: 35
Study 7802981 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Number of subjects: 41
Study 3047214 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 73
Study 3047214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 73
Study 3047214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 73
Study 3047214 — intervention group
Group type: COMPARATOR
Intervention: Control (Healthy subjects)
Number of subjects: 73
Study 31795883 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention using Orem's self-care model for eight sessions of 45-60 minutes
Number of subjects: 63
Study 31795883 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 63
Study 29135576 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted partner services (aPS)
Number of subjects: 500000
Study 29135576 — intervention group
Group type: COMPARATOR
Intervention: Program scenario of aPS
Number of subjects: 500000
Study 29135576 — intervention group
Group type: COMPARATOR
Intervention: Task-shifting scenario of aPS
Number of subjects: 500000
Study 28231975 — intervention group
Group type: EXPERIMENTAL
Intervention: Foraminal enlargement (FE) with a continuous rotary system
Number of subjects: 70
Study 28231975 — intervention group
Group type: COMPARATOR
Intervention: Nonforaminal enlargement (NFE)
Number of subjects: 70
Study 26147369 — intervention group
Group type: EXPERIMENTAL
Intervention: Virosomal vaccine H5N1 (NIBRG‐14) with Matrix M adjuvant (1.5, 7.5 or 30 μg HA)
Number of subjects: 60
Study 26147369 — intervention group
Group type: EXPERIMENTAL
Intervention: Virosomal vaccine H5N1 (NIBRG‐14) without Matrix M adjuvant (30 μg HA)
Number of subjects: 60
Study 26147369 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine (with or without Matrix M)
Number of subjects: 60
Study 24274213 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar drains (LDs)
Number of subjects: 150
Study 24274213 — intervention group
Group type: COMPARATOR
Intervention: No lumbar drains (LDs)
Number of subjects: 150
Study 24274213 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased intracranial pressure (ICP)
Number of subjects: 150
Study 24274213 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased ICP (both groups)
Number of subjects: 150
Study 21952595 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve stimulation technique (NS)
Number of subjects: 30
Study 21952595 — intervention group
Group type: COMPARATOR
Intervention: Loss of resistance technique (LOR)
Number of subjects: 30
Study 18469018 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized training program (n=24)
Number of subjects: 60
Study 18469018 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg rosiglitazone once daily (n=20)
Number of subjects: 60
Study 18469018 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=16)
Number of subjects: 60
Study 12565082 — intervention group
Group type: EXPERIMENTAL
Intervention: nisoldipine-ER (20 to 40 mg)
Number of subjects: 120
Study 12565082 — intervention group
Group type: COMPARATOR
Intervention: amlodipine (5 to 10 mg)
Number of subjects: 120
Study 12565082 — intervention group
Group type: EXPERIMENTAL
Intervention: nisoldipine-ER
Number of subjects: 120
Study 12565082 — intervention group
Group type: COMPARATOR
Intervention: amlodipine
Number of subjects: 120
Study 12565082 — intervention group
Group type: EXPERIMENTAL
Intervention: nisoldipine-ER and amlodipine
Number of subjects: 120
Study 9457948 — intervention group
Group type: EXPERIMENTAL
Intervention: Alloplastic barrier material
Number of subjects: 40
Study 9457948 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous peritoneal transplants
Number of subjects: 40
Study 9457948 — intervention group
Group type: COMPARATOR
Intervention: Visceral peritoneum injury
Number of subjects: 40
Study 7698380 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin dose increments at 20-min intervals
Number of subjects: 100
Study 7698380 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin dose increments at 60-min intervals
Number of subjects: 100
Study 2693231 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg nocte)
Number of subjects: 363
Study 2693231 — intervention group
Group type: COMPARATOR
Intervention: Sucralfate (1 g tds)
Number of subjects: 363
Study 356245 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (Voltaren) 125 mg daily
Number of subjects: 10
Study 356245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31726081 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation (tACS) synchronized with gait cycle frequency
Number of subjects: 8
Study 31726081 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 8
Study 31647695 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid
Number of subjects: 29
Study 27994091 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (E) therapy
Number of subjects: 353
Study 27994091 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (T)
Number of subjects: 353
Study 25804278 — intervention group
Group type: EXPERIMENTAL
Intervention: Virgin olive oil (OO) diet
Number of subjects: 45
Study 25804278 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm olein (PO) diet
Number of subjects: 45
Study 25804278 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut oil (CO) diet
Number of subjects: 45
Study 25804278 — intervention group
Group type: COMPARATOR
Intervention: Thrombogenicity indices and cell adhesion molecules
Number of subjects: 45
Study 23482999 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% mepivacaine (0.9 ml injected)
Number of subjects: 16
Study 23482999 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 16
Study 22610812 — intervention group
Group type: EXPERIMENTAL
Intervention: Sniffing position
Number of subjects: 400
Study 22610812 — intervention group
Group type: COMPARATOR
Intervention: Simple head extension
Number of subjects: 400
Study 22610812 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 400
Study 19841761 — intervention group
Group type: COMPARATOR
Intervention: Single Bond 2 (SB2)
Number of subjects: 40
Study 19841761 — intervention group
Group type: COMPARATOR
Intervention: Clearfil SE Bond (CSE)
Number of subjects: 40
Study 19841761 — intervention group
Group type: COMPARATOR
Intervention: Adper Prompt (ADP)
Number of subjects: 40
Study 16895768 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS patients (n = 30)
Number of subjects: 30
Study 16895768 — intervention group
Group type: COMPARATOR
Intervention: Control patients (n = 96)
Number of subjects: 30
Study 15645871 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonicare Advance power toothbrush
Number of subjects: 40
Study 15645871 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 40
Study 11358679 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 39
Study 11358679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 9014960 — intervention group
Group type: COMPARATOR
Intervention: Training once a week (1x/wk, n = 16)
Number of subjects: 58
Study 9014960 — intervention group
Group type: EXPERIMENTAL
Intervention: Training twice a week (2x/wk, n = 17)
Number of subjects: 58
Study 9014960 — intervention group
Group type: EXPERIMENTAL
Intervention: Training three times a week (3x/wk, n = 15)
Number of subjects: 58
Study 9014960 — intervention group
Group type: COMPARATOR
Intervention: Control group (C, n = 10)
Number of subjects: 58
Study 8204875 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial radiotherapy (cRT) plus prolonged triple intrathecal (IT) therapy with methotrexate (MTX), cytarabine, and prednisone.
Number of subjects: 93
Study 8204875 — intervention group
Group type: COMPARATOR
Intervention: No cranial radiotherapy (cRT) but prolonged triple IT therapy.
Number of subjects: 93
Study 8204875 — intervention group
Group type: COMPARATOR
Intervention: Neither cRT nor prolonged triple IT therapy.
Number of subjects: 93
Study 29804283 — intervention group
Group type: EXPERIMENTAL
Intervention: R:C ratio of 40:60
Number of subjects: 40
Study 29804283 — intervention group
Group type: EXPERIMENTAL
Intervention: R:C ratio of 80:20
Number of subjects: 40
Study 29804283 — intervention group
Group type: COMPARATOR
Intervention: LRC inclusion
Number of subjects: 40
Study 27274331 — intervention group
Group type: EXPERIMENTAL
Intervention: Video podcasts
Number of subjects: 41
Study 27274331 — intervention group
Group type: EXPERIMENTAL
Intervention: Written handouts
Number of subjects: 41
Study 27274331 — intervention group
Group type: COMPARATOR
Intervention: Comparison of podcasts vs handouts
Number of subjects: 41
Study 23948001 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational tobacco cessation treatment combined with nicotine replacement
Number of subjects: 224
Study 23948001 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 224
Study 22329473 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (starting dose of 5 mg increased up to 20 mg over four weeks, then stable dose of 20 mg from four to eight weeks)
Number of subjects: 29
Study 22329473 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching pill)
Number of subjects: 29
Study 20151970 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion SR 150 mg/daily
Number of subjects: 232
Study 20151970 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 232
Study 19375168 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal perfluoropropane (C3F8) gas injection (group A)
Number of subjects: 231
Study 19375168 — intervention group
Group type: COMPARATOR
Intervention: Pars plana vitrectomy (PPV) with intraocular C3F8 gas tamponade (group B)
Number of subjects: 231
Study 19375168 — intervention group
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy with concomitant internal limiting membrane (ILM) peeling
Number of subjects: 231
Study 19375168 — intervention group
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy without ILM peeling
Number of subjects: 231
Study 19375168 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative best-corrected visual acuity
Number of subjects: 231
Study 16974189 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion XL (300-450 mg/d)
Number of subjects: 348
Study 16974189 — intervention group
Group type: COMPARATOR
Intervention: venlafaxine XR (150-225 mg/d)
Number of subjects: 348
Study 16974189 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion XL
Number of subjects: 348
Study 16974189 — intervention group
Group type: COMPARATOR
Intervention: venlafaxine XR
Number of subjects: 348
Study 12764337 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine with ibuprofen
Number of subjects: 102
Study 12764337 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen alone
Number of subjects: 102
Study 12764337 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine
Number of subjects: 102
Study 12764337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 11195030 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg LPS
Number of subjects: 7
Study 11195030 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 microg LPS
Number of subjects: 7
Study 11195030 — intervention group
Group type: COMPARATOR
Intervention: 0 microg LPS (saline treatment)
Number of subjects: 7
Study 9068541 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute caffeine ingestion
Number of subjects: 0
Study 8349477 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (10 mg)
Number of subjects: 78
Study 8349477 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 78
Study 8349477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 3539741 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 79
Study 3539741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 30098076 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 6 mg/d orally from 3 days before surgery to 3 days after surgery
Number of subjects: 60
Study 30098076 — intervention group
Group type: COMPARATOR
Intervention: Vehicle treatment in rats
Number of subjects: 60
Study 30098076 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo treatment in patients
Number of subjects: 60
Study 26223941 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide (TED) 0.05 mg/kg daily subcutaneous
Number of subjects: 8
Study 26223941 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 8
Study 24258773 — intervention group
Group type: EXPERIMENTAL
Intervention: IV famotidine 12 mg/m²
Number of subjects: 24
Study 24258773 — intervention group
Group type: COMPARATOR
Intervention: IV ranitidine 60 mg/m²
Number of subjects: 24
Study 22321909 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (noradrenergic antagonist)
Number of subjects: 0
Study 22321909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20147856 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral S-1 (60 mg/m/d, twice a day) from days 1 to 14 with gemcitabine (1000 mg/m/d) on days 1 and 8 (arm A)
Number of subjects: 80
Study 20147856 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral S-1 (60 mg/m/d, twice a day) from days 1 to 14 with gemcitabine (1000 mg/m/d) on days 8 and 15 (arm B)
Number of subjects: 80
Study 18528312 — intervention group
Group type: EXPERIMENTAL
Intervention: Ossiculoplasty (OP)
Number of subjects: 39
Study 18528312 — intervention group
Group type: COMPARATOR
Intervention: Intact native chain reconstruction (INCR)
Number of subjects: 39
Study 16115299 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg twice daily
Number of subjects: 65
Study 16115299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 12501031 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of medical television drama
Number of subjects: 820
Study 12501031 — intervention group
Group type: EXPERIMENTAL
Intervention: Practical knowledge of cardiopulmonary resuscitation techniques
Number of subjects: 820
Study 12501031 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of drama consumption and practical knowledge
Number of subjects: 820
Study 12501031 — intervention group
Group type: EXPERIMENTAL
Intervention: Practical knowledge of basic cardiopulmonary resuscitation techniques
Number of subjects: 820
Study 10525698 — intervention group
Group type: EXPERIMENTAL
Intervention: STG-endobutton
Number of subjects: 14
Study 10525698 — intervention group
Group type: COMPARATOR
Intervention: Control (BTB autograft)
Number of subjects: 14
Study 8749732 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbo spin-echo (TSE) T2-weighted pulse sequences
Number of subjects: 78
Study 8749732 — intervention group
Group type: COMPARATOR
Intervention: Conventional spin-echo (CSE) T2-weighted images
Number of subjects: 78
Study 8749732 — intervention group
Group type: COMPARATOR
Intervention: Gradient-echo (GE) sequence
Number of subjects: 78
Study 2029414 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 0
Study 2029414 — intervention group
Group type: COMPARATOR
Intervention: External-beam radiation therapy
Number of subjects: 0
Study 7299867 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 gm/6 hours cefamandole
Number of subjects: 120
Study 7299867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 31931924 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal bupivacaine (20 ml 0.5% bupivacaine in 480 ml normal saline)
Number of subjects: 110
Study 31931924 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (500 ml)
Number of subjects: 110
Study 31931924 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal bupivacaine
Number of subjects: 110
Study 31931924 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 110
Study 31640736 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine and folic acid
Number of subjects: 4
Study 31640736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 27767991 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3293 (15 mg QD)
Number of subjects: 47
Study 27767991 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3293 (50 mg QD)
Number of subjects: 47
Study 27767991 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3293 (≥5 mg single dose)
Number of subjects: 47
Study 25899791 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg, single oral dose)
Number of subjects: 40
Study 24042024 — intervention group
Group type: EXPERIMENTAL
Intervention: Any oral NSAIDs
Number of subjects: 4203
Study 24042024 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-aspirin NSAIDs
Number of subjects: 4203
Study 24042024 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 4203
Study 24042024 — intervention group
Group type: COMPARATOR
Intervention: Highest users of NSAIDs
Number of subjects: 4203
Study 24042024 — intervention group
Group type: COMPARATOR
Intervention: Highest users of non-aspirin NSAIDs
Number of subjects: 4203
Study 24042024 — intervention group
Group type: COMPARATOR
Intervention: Highest users of low-dose aspirin
Number of subjects: 4203
Study 20602474 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative coronary artery revascularization (PR)
Number of subjects: 109
Study 20602474 — intervention group
Group type: COMPARATOR
Intervention: No preoperative coronary artery revascularization (no PR)
Number of subjects: 109
Study 20602474 — intervention group
Group type: COMPARATOR
Intervention: No PR
Number of subjects: 109